Product Datasheet
|
|
| |
| Product Description |
| |
| Product: |
COVID-19 Convalescent Patient Antibody, RBD Affinity Purified |
| Catalog Number: |
COVID-GF-HT |
| Product Page: |
https://www.mol-innov.com/products/ |
| Description: |
SARS-CoV-2 is the novel coronavirus that causes CoronaVirus Disease 2019 (COVID-19). This antibody preparation is affinity purified by immobilized recombinant receptor-binding domain (RBD) of the SARS-CoV-2 spike protein from Protein A/G purified IgG from pooled sera collected from convalescent COVID-19 patients. Serum was collected at least two weeks post symptom development from patients with positive COVID-19 PCR and serology tests. This antibody preparation is strongly positive in the Molecular Innovations SARS-CoV-2 IgG Seroconversion ELISA Kit and is useful as a positive control or calibrator in a variety of serological assays. Add deionized water to original volume, aliquot and freeze unused portion. |
| Recommended Storage: |
SAMPLE |
| Minimum Shelf Life: |
206.50 |
| Source: |
Lyophilized |
| Molecular Weight: |
Antibodies |
| Extinction Coefficient: |
160,000 |
| Antigen: |
-20 C |
| Target: |
Lyophilized powder
|
| Target Molecular Weight: |
COVID-19 |
| Host: |
836.5 |
| Clonality: |
30 |
| Isotype: |
Human serum |
| Clone: |
s |
| Applications: |
Cold pack |
| Cross-reactivity: |
5 years from delivery
|
| Concentration: |
295 |
| Volume: |
1195 |
| Titer: |
0.1M Tris-HCl; 0.15M NaCl pH 7.4
|
| Buffer: |
SAMPLE |
| Form: |
0.01 ml |
| Preservative: |
0.01 ml before lyophilization |
| |
| Optimal experimental conditions and working dilutions must be determined by the end user. Sample concentration and volume are for example purposes only and do not necessarily represent the product that will be received. Please contact us for a current lot-specific product datasheet. |
| |
| For in vitro laboratory use only |
| |
Molecular Innovations, Inc. - 46430 Peary Court, Novi, MI 48377, USA
Tel: (888) 557-5055 - Fax: (248) 896-0148 - info@mol-innov.com |